388 related articles for article (PubMed ID: 25407390)
1. Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.
Lim SM; Eom HN; Jiang HH; Sohn M; Lee KC
J Pharm Sci; 2015 Jan; 104(1):72-80. PubMed ID: 25407390
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres.
Liu B; Dong Q; Wang M; Shi L; Wu Y; Yu X; Shi Y; Shan Y; Jiang C; Zhang X; Gu T; Chen Y; Kong W
Chem Pharm Bull (Tokyo); 2010 Nov; 58(11):1474-9. PubMed ID: 21048339
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
[TBL] [Abstract][Full Text] [Related]
4. Preparation of uniform-sized exenatide-loaded PLGA microspheres as long-effective release system with high encapsulation efficiency and bio-stability.
Qi F; Wu J; Fan Q; He F; Tian G; Yang T; Ma G; Su Z
Colloids Surf B Biointerfaces; 2013 Dec; 112():492-8. PubMed ID: 24075786
[TBL] [Abstract][Full Text] [Related]
5. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes.
Kim H; Park H; Lee J; Kim TH; Lee ES; Oh KT; Lee KC; Youn YS
Biomaterials; 2011 Feb; 32(6):1685-93. PubMed ID: 21126761
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
[TBL] [Abstract][Full Text] [Related]
7. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity.
Kim TH; Jiang HH; Park CW; Youn YS; Lee S; Chen X; Lee KC
J Control Release; 2011 Feb; 150(1):63-9. PubMed ID: 21062635
[TBL] [Abstract][Full Text] [Related]
8. A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres.
Kim H; Jeong D; Kang HE; Lee KC; Na K
J Pharm Pharmacol; 2013 Jan; 65(1):11-21. PubMed ID: 23215683
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide-loaded poly(lactic-co-glycolic acid) microspheres: Preparation and in vivo evaluation.
Wu J; Williams GR; Branford-White C; Li H; Li Y; Zhu LM
Eur J Pharm Sci; 2016 Sep; 92():28-38. PubMed ID: 27343696
[TBL] [Abstract][Full Text] [Related]
10. Exenatide-loaded PLGA microspheres with improved glycemic control: in vitro bioactivity and in vivo pharmacokinetic profiles after subcutaneous administration to SD rats.
Xuan J; Lin Y; Huang J; Yuan F; Li X; Lu Y; Zhang H; Liu J; Sun Z; Zou H; Chen Y; Gao J; Zhong Y
Peptides; 2013 Aug; 46():172-9. PubMed ID: 23770254
[TBL] [Abstract][Full Text] [Related]
11. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
DeYoung MB; MacConell L; Sarin V; Trautmann M; Herbert P
Diabetes Technol Ther; 2011 Nov; 13(11):1145-54. PubMed ID: 21751887
[TBL] [Abstract][Full Text] [Related]
12. Construction and performance of exendin-4-loaded chitosan-PLGA microspheres for enhancing implant osseointegration in type 2 diabetic rats.
Shi S; Song S; Liu X; Zhao G; Ding F; Zhao W; Zhang S; Song Y; Ma W
Drug Deliv; 2022 Dec; 29(1):548-560. PubMed ID: 35156499
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the preparation progress of protein/peptide drug loaded PLA/PLGA microspheres.
Xu FH; Zhang Q
Yao Xue Xue Bao; 2007 Jan; 42(1):1-7. PubMed ID: 17520799
[TBL] [Abstract][Full Text] [Related]
14. Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes.
Kim H; Lee J; Kim TH; Lee ES; Oh KT; Lee DH; Park ES; Bae YH; Lee KC; Youn YS
Pharm Res; 2011 Aug; 28(8):2008-19. PubMed ID: 21472489
[TBL] [Abstract][Full Text] [Related]
15. Preparation and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(D,L-lactic-co-glycolic acid) microspheres using a double emulsion/solvent evaporation technique.
Karal-Yılmaz O; Serhatlı M; Baysal K; Baysal BM
J Microencapsul; 2011; 28(1):46-54. PubMed ID: 21171816
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies on the influences of primary emulsion preparation on properties of uniform-sized exenatide-loaded PLGA microspheres.
Qi F; Wu J; Hao D; Yang T; Ren Y; Ma G; Su Z
Pharm Res; 2014 Jun; 31(6):1566-74. PubMed ID: 24398695
[TBL] [Abstract][Full Text] [Related]
18. [Long-acting injectable microspheres of glucagon-like peptide-1].
Yin DF; Wu C; Lu Y; Zhu Y; Zhong YQ
Yao Xue Xue Bao; 2006 Jul; 41(7):603-7. PubMed ID: 17007350
[TBL] [Abstract][Full Text] [Related]
19. Characterization of attributes and in vitro performance of exenatide-loaded PLGA long-acting release microspheres.
Li T; Chandrashekar A; Beig A; Walker J; Hong JKY; Benet A; Kang J; Ackermann R; Wang Y; Qin B; Schwendeman AS; Schwendeman SP
Eur J Pharm Biopharm; 2021 Jan; 158():401-409. PubMed ID: 33122118
[TBL] [Abstract][Full Text] [Related]
20. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
Lee C; Choi JS; Kim I; Oh KT; Lee ES; Park ES; Lee KC; Youn YS
Int J Nanomedicine; 2013; 8():2975-83. PubMed ID: 23976850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
